Compare CVU & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVU | CVM |
|---|---|---|
| Founded | 1980 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 53.1M |
| IPO Year | N/A | 1987 |
| Metric | CVU | CVM |
|---|---|---|
| Price | $4.40 | $5.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 211.4K | 70.4K |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $71,616,326.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $1.98 |
| 52 Week High | $5.85 | $20.41 |
| Indicator | CVU | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 73.31 | 46.10 |
| Support Level | $3.87 | $5.01 |
| Resistance Level | $4.20 | $6.37 |
| Average True Range (ATR) | 0.25 | 0.55 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 82.24 | 63.41 |
CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States. It also provides engineering, program management, supply chain management and kitting, and Maintenance Repair and Overhaul (MRO) services. CPI also acts as a subcontractor to prime aircraft manufacturers in the production of commercial aircraft parts. CPI Aero supplies the E-2D Advanced Hawkeye surveillance aircraft, the A-10 Thunderbolt attack jet, the Gulfstream G650, the UH-60 BLACK HAWK helicopter, and the S-92 helicopter, and others.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.